10X Genomics
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 299m | 490m | 516m | 619m | 647m | 717m | 789m |
% growth | 22 % | 64 % | 5 % | 20 % | 5 % | 11 % | 10 % |
EBITDA | (82.5m) | (53.5m) | (161m) | (205m) | (138m) | (89.2m) | 14.8m |
% EBITDA margin | (28 %) | (11 %) | (31 %) | (33 %) | (21 %) | (12 %) | 2 % |
Profit | (543m) | (58.2m) | (166m) | (255m) | (159m) | (109m) | (47.6m) |
% profit margin | (182 %) | (12 %) | (32 %) | (41 %) | (25 %) | (15 %) | (6 %) |
EV / revenue | 48.8x | 32.7x | 7.2x | 10.1x | 3.8x | 3.4x | 2.8x |
EV / EBITDA | -176.8x | -300.0x | -23.2x | -30.4x | -17.9x | -27.0x | 151.7x |
R&D budget | 123m | 212m | 266m | 331m | - | - | - |
R&D % of revenue | 41 % | 43 % | 51 % | 54 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $3.0m | Series A | |
N/A | $22.4m | Series A | |
$55.5m | Series B | ||
$55.0m | Series C | ||
$50.0m | Series D | ||
$75.0m | Debt | ||
* | $35.0m Valuation: $1.3b 8.9x EV/LTM Revenues -12.3x EV/LTM EBITDA | Late VC | |
N/A | $390m Valuation: $3.7b 25.3x EV/LTM Revenues -34.9x EV/LTM EBITDA | IPO | |
* | N/A | N/A | Post IPO Equity |
Total Funding | €201m |
Recent News about 10X Genomics
Edit10x Genomics is a biotechnology company that focuses on advancing genomic research through innovative products and solutions. The company operates primarily in the life sciences sector, serving academic, clinical, and pharmaceutical researchers. Their main offerings include tools and technologies for single-cell analysis, spatial gene expression, and immune profiling. These tools help scientists understand complex biological systems by analyzing genetic information at a very detailed level.
The market 10x Genomics operates in is highly specialized and rapidly growing, driven by the increasing demand for personalized medicine and advanced research capabilities. Their clients are typically research institutions, universities, hospitals, and pharmaceutical companies that require high-resolution genomic data to drive their studies and develop new treatments.
10x Genomics' business model revolves around selling advanced laboratory equipment and consumables, such as reagents and microfluidic chips, which are essential for conducting genomic experiments. Additionally, they offer software solutions that help researchers analyze and interpret the vast amounts of data generated by their experiments. The company generates revenue through the sale of these products and services, as well as through ongoing support and training for their clients.
In summary, 10x Genomics is a key player in the genomic research field, providing cutting-edge tools and solutions that enable scientists to explore and understand the complexities of the human genome. Their focus on innovation and high-quality products has positioned them as a leader in this niche market.
Keywords: Genomics, Biotechnology, Single-cell analysis, Spatial gene expression, Immune profiling, Research tools, Life sciences, Personalized medicine, Data analysis, Laboratory equipment.